Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 610

1.

Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia.

Palraj BR, Baddour LM, Hess EP, Steckelberg JM, Wilson WR, Lahr BD, Sohail MR.

Clin Infect Dis. 2015 Mar 25. pii: civ235. [Epub ahead of print]

PMID:
25810284
2.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Konopleva M, Thall PF, Arana Yi C, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H.

Haematologica. 2015 Feb 14. pii: haematol.2014.118455. [Epub ahead of print]

3.

Predicting Risk of Endovascular Device Infection in Patients With Staphylococcus aureus Bacteremia (PREDICT-SAB).

Sohail MR, Palraj BR, Khalid S, Uslan DZ, Al-Saffar F, Friedman PA, Hayes DL, Lohse CM, Wilson WR, Steckelberg JM, Baddour LM.

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):137-44. doi: 10.1161/CIRCEP.114.002199. Epub 2014 Dec 12.

PMID:
25504648
4.

Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.

Gu Y, Jaiswal JK, Wang J, Hicks KO, Hay MP, Wilson WR.

J Pharm Sci. 2014 Nov;103(11):3464-72. doi: 10.1002/jps.24099. Epub 2014 Sep 11.

PMID:
25212501
5.

Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.

Hunter FW, Hsu HL, Su J, Pullen SM, Wilson WR, Wang J.

Mol Cancer Ther. 2014 Nov;13(11):2501-14. doi: 10.1158/1535-7163.MCT-14-0476. Epub 2014 Sep 5.

PMID:
25193512
6.

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.

Wang J, Guise CP, Dachs GU, Phung Y, Hsu AH, Lambie NK, Patterson AV, Wilson WR.

Biochem Pharmacol. 2014 Oct 15;91(4):436-46. doi: 10.1016/j.bcp.2014.08.003. Epub 2014 Aug 15.

PMID:
25130546
7.

Pregnancy and postpartum infective endocarditis: a systematic review.

Kebed KY, Bishu K, Al Adham RI, Baddour LM, Connolly HM, Sohail MR, Steckelberg JM, Wilson WR, Murad MH, Anavekar NS.

Mayo Clin Proc. 2014 Aug;89(8):1143-52. doi: 10.1016/j.mayocp.2014.04.024. Epub 2014 Jul 1. Review.

PMID:
24997091
8.

Desulfovibrio legallii prosthetic shoulder joint infection and review of antimicrobial susceptibility and clinical characteristics of Desulfovibrio infections.

Vasoo S, Mason EL, Gustafson DR, Cunningham SA, Cole NC, Vetter EA, Steinmann SP, Wilson WR, Patel R, Berbari EF, Henry NK.

J Clin Microbiol. 2014 Aug;52(8):3105-10. doi: 10.1128/JCM.00083-14. Epub 2014 May 21.

9.

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.

Bonnet M, Hong CR, Gu Y, Anderson RF, Wilson WR, Pruijn FB, Wang J, Hicks KO, Hay MP.

Bioorg Med Chem. 2014 Apr 1;22(7):2123-32. doi: 10.1016/j.bmc.2014.02.039. Epub 2014 Mar 3.

PMID:
24650701
10.

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

Hunter FW, Jaiswal JK, Hurley DG, Liyanage HD, McManaway SP, Gu Y, Richter S, Wang J, Tercel M, Print CG, Wilson WR, Pruijn FB.

Biochem Pharmacol. 2014 May 15;89(2):224-35. doi: 10.1016/j.bcp.2014.03.001. Epub 2014 Mar 13.

PMID:
24632291
11.

Targeting hypoxia in the leukemia microenvironment.

Benito J, Zeng Z, Konopleva M, Wilson WR.

Int J Hematol Oncol. 2013 Aug 1;2(4):279-288.

12.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.

Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.

PMID:
24434189
13.

Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Foehrenbacher A, Secomb TW, Wilson WR, Hicks KO.

Front Oncol. 2013 Dec 27;3:314. doi: 10.3389/fonc.2013.00314. Review.

14.

Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients.

Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Sohail MR.

Am J Kidney Dis. 2014 Jul;64(1):104-10. doi: 10.1053/j.ajkd.2013.11.018. Epub 2014 Jan 3.

PMID:
24388672
15.

Euthermic endocarditis.

DeSimone DC, Baddour LM, Lahr BD, Chung HH, Wilson WR, Steckelberg JM; Mayo Cardiovascular Infections Study Group.

PLoS One. 2013 Nov 11;8(11):e80144. doi: 10.1371/journal.pone.0080144. eCollection 2013.

16.

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Su J, Gu Y, Pruijn FB, Smaill JB, Patterson AV, Guise CP, Wilson WR.

J Biol Chem. 2013 Dec 27;288(52):37138-53. doi: 10.1074/jbc.M113.505222. Epub 2013 Nov 6.

17.

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

Foehrenbacher A, Patel K, Abbattista MR, Guise CP, Secomb TW, Wilson WR, Hicks KO.

Front Oncol. 2013 Oct 7;3:263. doi: 10.3389/fonc.2013.00263. eCollection 2013.

18.

Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism.

Richter S, Morrison S, Connor T, Su J, Print CG, Ronimus RS, McGee SL, Wilson WR.

PLoS One. 2013 Jun 14;8(6):e65267. doi: 10.1371/journal.pone.0065267. Print 2013.

19.

Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs.

Chang JY, Lu GL, Stevenson RJ, Brothers PJ, Clark GR, Botting KJ, Ferry DM, Tercel M, Wilson WR, Denny WA, Ware DC.

Inorg Chem. 2013 Jul 1;52(13):7688-98. doi: 10.1021/ic4006967. Epub 2013 Jun 17.

PMID:
23773210
20.

18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.

Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, Wilson WR, Zalutsky MR, Dewhirst MW.

J Nucl Med. 2013 Aug;54(8):1339-46. doi: 10.2967/jnumed.112.116293. Epub 2013 Jun 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk